ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by ENDRA Life Sciences Inc. on September 27, 2022. The filing reports a material modification to the rights of security holders through the declaration of a dividend of Series C Preferred Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Series C Preferred Stock Dividend: On September 26, 2022, the Board declared a dividend of one one-thousandth (1/1,000) of a share of Series C Preferred Stock for each outstanding share of Common Stock, and 1.359 shares of Series C Preferred Stock for each outstanding share of Series A Convertible Preferred Stock.
- Record Date: Stockholders of record as of 5:00 p.m. Eastern Time on October 7, 2022, are eligible for the dividend.
- Voting Rights: Each whole share of Series C Preferred Stock (excluding those held by directors or named executive officers) carries 1,000,000 votes. Each fraction of a share carries a ratable number of votes (e.g., 1/1,000th of a share equals 1,000 votes).
- Scope of Voting: These shares vote exclusively on proposals to adopt a Reverse Stock Split. They do not vote on other matters except as required by Delaware law.
- Liquidation Preference: Series C Preferred Stock ranks senior to Common Stock, with a liquidation preference of $0.0001 per share.
- Redemption Terms: Shares not present at the meeting to vote on the Reverse Stock Split will be automatically redeemed for no consideration. Remaining shares will be redeemed for no consideration upon Board order or approval of the Reverse Stock Split.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the structural changes to the stock. The primary contingency is the potential redemption of the Series C Preferred Stock for no consideration if the Reverse Stock Split is approved or if shares are not present at the voting meeting.
Key Facts for Investor Verification
- Verify the exact number of Common and Series A Preferred shares outstanding to calculate the total Series C Preferred shares issued.
- Confirm the specific date and time of the stockholder meeting where the Reverse Stock Split will be voted upon.
- Review the Certificate of Designation (Exhibit 3.1) for complete legal terms regarding the Series C Preferred Stock.
- Monitor whether the Reverse Stock Split proposal is approved, as this triggers the automatic redemption of the Series C Preferred Stock.